The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial

Publication | Open Access

DOI Full Paper Access

Citations

References

2020

Year

David P. Dearnaley, Daniel R. Saltzstein, John E. Sylvester, Lawrence I. Karsh, Bryan A. Mehlhaff, Christopher Pieczonka, James L. Bailen, Hongliang Shi, Zhan Ye, Hélène M. Faessel,

European Urology

Abstract

References